Proposition - PharmXpert Academy

More documents

Recommendations

Info

The Korean Pharmaceutical Company List 431 34. KOREAN DRUG CO,.LTD 1. Company Information Company KOREAN DRUG CO,.LTD Representative Hai Ryong Park E-mail Representative Phone No. Hompage http://www.nicepharma.com/ Representative Fax No. Address 423- 2 Dogok-Dong Kangnam-Ku, Seoul, Korea Research Institute Address Year of Establishment The Number of Employees (06‘) 486 Sukwang-Ri Sindun-Myun, Icheon, Kyunggi, Korea 1980 Sales (‘06) 29.7 Million$ Total The Number of 248 Researcher (‘06) 23 Total Contact Person Byung-Moo, Jung Contact Phone (02) 529-6100-315 Contact E-mail bmjung@nicepharma.com Contact Fax (02) 529-6114 Introduction of Company During our first decade, we focused our efforts on Over The Counter (OTC) medicines. Haben series have been one of our most successful products. As a medium-sized firm, it was not easy for us to become the leading company in this market. The key factors for this success were the superiority of the product itself as well as the implementation of proper marketing strategy. Our second decade can be represented by the passion to develop prescription medicine. Our business is applying the latest advances of technology to make innovative medicines for treating human illness. Our progress today was build upon our challenging past. We are passionate about what we do. We apply that passion to serve the needs of our patients, the medical profession, and our employees based on the continuing pursuit of excellent science. We never forget that our efforts benefit people like you. That knowledge motivates us every day. Our passion has brought us to where we are today. In 1997, we launched Lansoprazole(Second generation proton pump inhibitor --- Anti-peptic ulcer agent). We were the first company in Korea to have developed Lansoprazole by our own R&D effort. Looking forward to the future, we are focusing our efforts toward developing medicines in the areas of gastrointestinal medicine and oncology, while also remaining open to the opportunities in other areas of disease. The company's R&D investment is a major initiative that will continue to fuel KDC's steady and reliable growth. This investment will enable the company to remain a valuable contributor to both its brand and generic market.
432 2007 Korea Pharmaceutical Industry Directory 2. Main Products Information No. The Name of Products Main Ingredient Use (Indications) Formulation The Date of Sales Expected Exporting Countries Etc. 1 Broncoban Tab Ambroxol,HCI cough, bronchial asthma tablet 2 Claroma Tab Clarithromycin Acute and chronic bronchitis tablet 3 Dalmadorm Tab Flurazepam·HCI chronic medical situations requiring restful sleep. tablet 4 Doxycycline Cap Doxycycline hyclate Broad spectrum antibiotics capsule 5 Hanacef Cap Cefadroxil monohydrate Broad spectrum antibiotics capsule 6 Hericoba Tab Tripotassium dicitrato bismuthate Treatment of gastric tablet 7 Lancid Cap Lansoprazole Gastric ulcer, duodenal ulcer capsule 8 Librax Tab Chlordiazepoxide Psychosomatic syndrome tablet 9 Mestinon Tab Pyridostigmine bromide Myasthenia gravis tablet 10 Monocin Tab Doxycycline hyclate Broad spectrum antibiotics tablet 3. R&D Figures □ Synthesis Team The synthesis Team was established in 1999 for import substitution of raw material medicine and the advance into foreign markets, Since then it has picked up speed in synthetic technology development of raw material medicine. As a result, in 1999, the synthetic technology development of Lansoprazole, the medicine for peptic ulcer and reflux esophagitis by Proton Pump Inhibitor, was completed. In 2000, Clarithromycin, Macrolide Antibiotics, that is effective on Helicobacter pylori, was manufactured. And in 2001, synthetic technology of Allyamine Anti-fungal agent was developed. Self-manufacturing technique of raw material medicine was effective on import substitution of raw material medicine and served as a stepping-stone for individual marketing toward foreign markets.
Page 2 and 3:
2007 Korea Pharmaceutical Industry
Page 4 and 5:
2007 Korea Pharmaceutical Industry
Page 6 and 7:
27. ILYANG PHARM ·········
Page 8 and 9:
Chapter 1. Outline of The Project 2
Page 10 and 11:
Chapter 1. Outline of The Project 2
Page 12 and 13:
Chapter 2. Pharmaceutical Industry
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
The Annex
Page 38 and 39:
316 2007 Korea Pharmaceutical Indus
Page 40 and 41:
The Korean Pharmaceutical Company L
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
4. Company Map The Korean Pharmace
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103: The Korean Pharmaceutical Company L
Page 200 and 201: 4. Company Map The Korean Pharmace
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
show all

Proposition - PharmXpert Academy

Create successful ePaper yourself

Delete template?

Save as template?